156 related articles for article (PubMed ID: 36149183)
1. Acute myeloid leukemia and myelofibrosis: Simultaneous transformation of essential thrombocythemia during treatment with hydroxyurea.
Nalluru SS; Efe O; Chen Y; Trivedi N
J Cancer Res Ther; 2022; 18(4):1180-1182. PubMed ID: 36149183
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
3. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
Chim CS; Kwong YL; Lie AK; Ma SK; Chan CC; Wong LG; Kho BC; Lee HK; Sim JP; Chan CH; Chan JC; Yeung YM; Law M; Liang R
Arch Intern Med; 2005 Dec 12-26; 165(22):2651-8. PubMed ID: 16344424
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
6. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
7. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
Furgerson JL; Vukelja SJ; Baker WJ; O'Rourke TJ
Am J Hematol; 1996 Feb; 51(2):137-40. PubMed ID: 8579054
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
11. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
Li Y; Zhang XY; Han J; Wang L
Cancer Biomark; 2018; 23(4):469-472. PubMed ID: 30452397
[TBL] [Abstract][Full Text] [Related]
12. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
13. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia.
Park YH; Lee S; Mun YC; Park DJ
Cancer Med; 2023 Apr; 12(7):8073-8082. PubMed ID: 36622093
[TBL] [Abstract][Full Text] [Related]
16. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
[TBL] [Abstract][Full Text] [Related]
17. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
Löfvenberg E; Wahlin A
Eur J Haematol; 1988 Oct; 41(4):375-81. PubMed ID: 3197824
[TBL] [Abstract][Full Text] [Related]
18. IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.
Huang X; Ma T; Zhu Y; Jiao B; Yu S; Wang K; Mi JQ; Ren R
Front Med; 2022 Jun; 16(3):403-415. PubMed ID: 34331664
[TBL] [Abstract][Full Text] [Related]
19. A novel t(2;17) in transformation of essential thrombocythemia to acute myelocytic leukemia.
Lazarevic VLj; Tomin D; Jankovic GM; Antic D; Dencic M; Gotic M; Boskovic D
Cancer Genet Cytogenet; 2004 Jan; 148(1):77-9. PubMed ID: 14697645
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
